| Literature DB >> 21300061 |
Kristine E Nograles1, James G Krueger.
Abstract
Current approaches for the treatment of psoriasis with anti-cytokine therapies involve the blockade of TNF-α, or the p40 sub-unit of IL-12 and IL-23. However, the field is currently evolving to test more selective antagonists, such as anti-IL-23p19, IL-17 and other inflammatory cytokines. Here we discuss our current understanding of dendritic cell and T cell subsets that are relevant in psoriasis, and the pharmacologic strategies that temper their activity in this disease.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21300061 DOI： 10.1016/j.yexcr.2011.01.024
Source DB: PubMed Journal: Exp Cell Res ISSN： 0014-4827 Impact factor: 3.905